A型肉毒毒素与口服药物治疗膀胱过度活动症疗效比较的网状Meta分析
该系统综述与网状Meta分析纳入56项随机对照试验,比较A型肉毒毒素100 U、米拉贝隆及抗胆碱能药物对成人特发性膀胱过度活动症的疗效;治疗12周后,A型肉毒毒素100 U在减少尿失禁发作、急迫发作和排尿频率方面优于多数其他许可剂量药物。
要点
- 纳入56项随机对照试验,比较A型肉毒毒素、米拉贝隆和抗胆碱能药物治疗特发性膀胱过度活动症。
- 治疗12周后,A型肉毒毒素100 U在减少尿失禁发作、急迫发作和排尿频率方面平均改善最大。
- A型肉毒毒素100 U在尿失禁发作和急迫发作上优于所有对照药物,可信区间排除零。
核心结论
- 治疗12周后,A型肉毒毒素100 U对膀胱过度活动症症状的缓解程度大于网络中多数其他药物的许可剂量。
研究设计与样本
- 系统性综述与网状Meta分析,检索盲法随机对照试验,试验时长≥2周,比较A型肉毒毒素任意剂量、合格口服或透皮抗胆碱能药物或米拉贝隆之间或与安慰剂的疗效,纳入成人特发性膀胱过度活动症患者,共纳入56项随机对照试验。
- 采用贝叶斯随机效应模型在第12周合成结果:应答分析用网状Meta分析,基线变化分析用网状Meta回归,网状Meta回归校正研究间基线严重程度差异。
- 进行敏感性分析,排除方法学偏倚高风险的研 究。
主要发现
- 治疗12周后,所有治疗均比安慰剂更有效。
- A型肉毒毒素100 U组平均尿失禁发作、急迫发作和排尿频率减少最大,且尿失禁发作/天较基线减少100%和≥50%的比值比最高。
- A型肉毒毒素100 U与所有对照药物比较,尿失禁发作和急迫发作的平均差均有利于A型肉毒毒素100 U,可信区间排除零;排尿频率方面除两种对照药物外均有利于A型肉毒毒素100 U。
- A型肉毒毒素100 U在尿失禁发作/天减少100%和≥50%的比值比上高于网络中多数其他许可治疗。
- 排除高偏倚风险研究对结论影响很小。
关键数值与推荐
- 共纳入56项随机对照试验进入网络。
- 每种结局报告所有许可治疗剂量的结果;每个网状Meta回归结果基于基线时该结局平均发作次数的患者。
- A型肉毒毒素100 U在尿失禁发作和急迫发作上优于所有对照药物,平均差的可信区间排除零。
- A型肉毒毒素100 U在尿失禁发作/天减少100%和≥50%的比值比上高于多数其他许可治疗。
临床怎么用
- 原文未据此给出推荐。
- 原文结论指出A型肉毒毒素100 U在12周时对膀胱过度活动症症状的缓解大于网络中多数其他药物的许可剂量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the efficacy of onabotulinumtoxinA, mirabegron, and anticholinergics in adults with idiopathic overactive bladder (OAB) using network meta-analysis (NMA). PATIENTS AND METHODS: Information sources were searched for blinded randomised controlled trials (RCTs), of ≥2 weeks duration, comparing any dose of onabotulinumtoxinA, eligible oral/transdermal anticholinergics, or mirabegron, with each other or placebo, in adults with OAB. Bayesian random-effects models were used to synthesise the results at week 12: NMA for responder analyses and network meta-regression (NMR) for change from baseline analyses. The NMR was used to adjust for differences in baseline severity between studies. Sensitivity analysis, excluding studies considered to be at a high risk of methodological bias, was conducted. RESULTS: In all, 56 RCTs were included in the networks. For each outcome, results are reported for all licensed treatment doses. For each NMR, results are based on patients with an average number of episodes of the outcome at baseline. After 12 weeks, all treatments were more efficacious than placebo. Patients who received onabotulinumtoxinA (100 U) had, on average, the greatest reductions in urinary incontinence episodes (UIE), urgency episodes, and micturition frequency, and the highest odds of achieving decreases of 100% and ≥50% from baseline in UIE/day. When comparing onabotulinumtoxinA with other pharmacotherapies, mean differences favoured onabotulinumtoxinA 100 U over all comparators for UIE and urgency episodes (credible intervals excluded zero) and all but two of the comparators for micturition frequency. OnabotulinumtoxinA 100 U was also associated with higher odds of achieving a 100% and ≥50% decrease in UIE/day than most other licensed treatments in the network. The exclusion of studies with a high risk of bias had little impact on the conclusions. CONCLUSION: The results indicate that, after 12 weeks, onabotulinumtoxinA 100 U provides greater relief of OAB symptoms compared with most other licensed doses of other pharmacotherapies in the network.
引用
- Drake MJ, Nitti VW, Ginsberg DA, et al. Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int. 2017. PMID: 28670786. doi:10.1111/bju.13945
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。